| |
Newsroom /
Health and Fitness
/
Healthcare
/
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016
The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 
The Global Pain Management Market Is Forecast to Grow Moderately, As Generic Share Continues to Rise
kent,
sidcup,
United Kingdom
(prbd.net)
30/03/2010
"The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 "
In 2009, the global pain management market was approximately $18.3 billion, representing a compound annual growth rate (CAGR) of 5.3% between 2001 and 2009. By 2016, the global pain management market is estimated to reach $22.6 billion, indicating a CAGR of 3% between 2009 and 2016. The major reason behind the decline in the growth rate is the decline in the annual cost of treating pain in different indications during 2009-2016.
The global pain management market is expected to witness a series of patent expiries between 2009 and 2016, which includes some top selling drugs such as Cymbalta (duloxetine HCl), Lyrica pregabalin) and Celebrex (celecoxib). These drugs together, account for approximately 45% of the market. Other drugs that will lose patent protection are Maxalt (rizatriptan benzoate), Zomig (zolmitriptan), Axert (almotriptan malate), Amerge (Naratriptan) and Quadramet (samarium SM 153 lexidronam), among others. While the current pain management market has a healthy pipeline and prospects for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Therefore while the pipeline ensures a potential for attractive growth in the long term, the market will grow only at a moderate CAGR of 3% during the period 2009-2016.
The research and development (R&D) pipeline for pain management is moderately healthy due to the presence of about 400 programs. These programs study drug candidates for the treatment of neuropathic pain and pain associated with fibromyalgia, cancer, migraine and osteoarthritis. However, the products in the pipeline do not look promising and may not provide better efficacy and safety levels compared to the drugs currently in the market. The pipeline is mix of first-in-class and me-too products. The success of the first-in-class products will determine the future prospects for the industry. The high R&D activity indicates that the pain management market has potential for growth.
The market has large diseased population which is under-served. The treatment seeking behavior is poor at less than 50% of the total diseased patients. The treatment seeking rate is expected to increase only marginally compared to historic growth. Therefore in the long run, a huge untapped market will remain to be targeted by companies that manufacture pain management products.
GBI Research, the leading business intelligence provider, has released its latest research, “The Future of Pain Management Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Generic Competition Creates Challenges”. It provides in-depth analysis of unmet needs, drivers and barriers that impact the global pain management therapeutics market. The report analyzes the markets for pain management in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
http://www.gbiresearch.com
About
GBI Research is a global market intelligence services company providing information research and analysis products and services.
|